These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37867512)

  • 1. Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus.
    Wang L; Liang C; Song X; Jia X; Wang X; Zhang Y; Xie Q; Zheng N; Yuan H
    Front Endocrinol (Lausanne); 2023; 14():1256292. PubMed ID: 37867512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
    Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
    BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
    Ali AM; Mari A; Martinez R; Al-Jobori H; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32745202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.
    Yang M; Yue H; Xu Q; Shao S; Chen Y
    Diabetes Obes Metab; 2024 Aug; 26(8):3137-3146. PubMed ID: 38699792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S; Chow W; Korrer S; Aguilar R
    Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
    Tanton D; Duh MS; Lafeuille MH; Lefebvre P; Pilon D; Zhdanava M; Emond B; Inman D; Bailey RA
    Curr Med Res Opin; 2018 Jun; 34(6):1099-1115. PubMed ID: 29468896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting.
    Chow W; Buysman E; Rupnow MF; Aguilar R; Henk HJ
    Curr Med Res Opin; 2016; 32(1):13-22. PubMed ID: 26414434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of "maccog" TCM tea on improving glucolipid metabolism and gut microbiota in patients with type 2 diabetes in community.
    Hu B; Yin T; Zhang J; Liu M; Yun H; Wang J; Guo R; Huang J; Zhou Y; Meng H; Wang L
    Front Endocrinol (Lausanne); 2023; 14():1134877. PubMed ID: 36967788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.
    Rosenstock J; Chuck L; González-Ortiz M; Merton K; Craig J; Capuano G; Qiu R
    Diabetes Care; 2016 Mar; 39(3):353-62. PubMed ID: 26786577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
    Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Rose JB; Sorabji D; Bajaj HS
    Can J Diabetes; 2019 Oct; 43(7):464-471. PubMed ID: 31133438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study.
    Gao Y; Zhao T; Lv N; Liu S; Yuan T; Fu Y; Zhao W; Zhu B
    Endocrine; 2024 Sep; 85(3):1178-1192. PubMed ID: 38761345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease.
    Wang X; Wang Z; Liu D; Jiang H; Cai C; Li G; Yu G
    Front Pharmacol; 2022; 13():839640. PubMed ID: 35281938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
    Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
    Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
    Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Culham MD; Rose JB; Rapattoni W; Bajaj HS
    Diabetes Obes Metab; 2019 Mar; 21(3):691-699. PubMed ID: 30393961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the Gut Microbiota in Pregnant Women with Pregestational Type 2 Diabetes Mellitus.
    Ren Y; Hao L; Liu J; Wang P; Ding Q; Chen C; Song Y
    mSystems; 2023 Apr; 8(2):e0114622. PubMed ID: 36853013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA
    Ali AM; Martinez R; Al-Jobori H; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes Care; 2020 Jun; 43(6):1234-1241. PubMed ID: 32220916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential mechanism of Liu-Wei-Di-Huang Pills in treatment of type 2 diabetic mellitus: from gut microbiota to short-chain fatty acids metabolism.
    Yi ZY; Chen L; Wang Y; He D; Zhao D; Zhang SH; Yu R; Huang JH
    Acta Diabetol; 2022 Oct; 59(10):1295-1308. PubMed ID: 35857109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of short-chain fatty acids and the gut microbiome with type 2 diabetes: Evidence from the Henan Rural Cohort.
    Yang T; Wu C; Li Y; Wang C; Mao Z; Huo W; Li J; Li Y; Xing W; Li L
    Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1619-1630. PubMed ID: 38653672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
    Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X
    Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.